Apterna’s lead programme is designed to restore liver function in patients whose disease currently prevents access to curative care. It begins with liver cancer patients denied surgery because their liver reserve is too poor, with broader future relevance across cirrhosis, transplant avoidance, and fatty liver disease as evidence builds.
From Discovery to Translation: Building the Next Generation of RNA Therapeutics
A Portfolio Anchored in Precision Delivery
Apterna’s programmes are built around two validated, organ-targeted delivery platforms:
Liver Surgery Unlock
Initial focus on patients denied potentially curative surgery because their liver reserve is too poor.
Cirrhosis and Transplant Avoidance
Next horizon in advanced liver dysfunction, where restoring liver function could help delay or avoid transplant.
Fatty Liver Disease and Obesity
Longer-term expansion into the largest liver disease market, positioned as a complement to GLP-1 therapies rather than a competitor.
Apterna's Development Programmes
Current outline of our active and emerging programmes. Timelines reflect planned progression from preclinical to early clinical development.
| Programme | Disease Area | Strategic Role | Initial Focus | Stage | Next Milestone |
|---|---|---|---|---|---|
| REGEN001 | Liver Surgery Unlock | Lead programme | Liver cancer patients denied potentially curative surgery because liver reserve is too poor | Preclinical | Lead selection and in vitro proof of concept |
| REGEN001 | Cirrhosis / Transplant Avoidance | Horizon 2 expansion | Advanced liver dysfunction beyond the initial surgical setting | Future Expansion |
Enabled by proof of concept in the lead indication |
| REGEN001 | Fatty Liver Disease / Obesity | Horizon 3 expansion | Broader liver disease opportunity as evidence builds across the disease continuum | Longer-Term Expansion |
Strategic expansion following validation in earlier liver settings |
Collaborate With Us to Advance Precision RNA Medicine
Apterna offers multiple engagement models for pharmaceutical and academic partners
Co-Development
Joint work on specific disease indications
Platform Licensing
Access to liver or brain delivery systems for proprietary RNA payloads
Collaborative Research
Shared preclinical studies to accelerate validation
Our goal is to build partnerships that expand the therapeutic reach of RNA medicine while maintaining rigorous scientific and ethical standards.
From Precision Science to Real-World Impact
Apterna’s pipeline is built to deliver measurable patient benefit through safe, targeted RNA delivery. By combining validated chemistry, scalable design, and translational expertise, we aim to move beyond theoretical potential — toward a new generation of clinically meaningful RNA therapeutics.